Dirk Sibbing Shares Phase 3 Study on Dissaggpro for STEMI – Rapid Onset and Fast Offset of Antiplatelet Action!
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”A new drug on the horizon for pre-hospital treatment of STEMI patients
Subcutaneous GPIIb/IIIa – Dissaggpro
Rapid onset and fast offset of antiplatelet action
Phase 3 Study (CeleBrate) of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results as announced by CeleCor Therapeutics
This, for sure, will bring new aspects into the discussions on pretreatment (antiplatelet) for STEMI patients…
Still we are loosing too many patients pre-hospital and before we see them in the cath lab…
Results will be presented as LBCT at AHA 2025 in New Orleans
Arnoud van ‘t Hof, Robert S. Hillman, Jur ten Berg, C. Michael Gibson, M.S., M.D.”
Read the full article here.
Article: Phase 3 Study of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results
Stay updated on all scientific advances in the field with Hemostasis Today.
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH
-
Jan 8, 2026, 03:47Wolfgang Miesbach on Fernando Corrales-Medina’s Team’s Latest Cross-Sectional Study on Haemophilia
-
Jan 8, 2026, 03:28Rick Matthews: Powerful Perspective from Erin and the NBCA Team